Pharmafile Logo
Pharmafocus logo
Advanced Search

Orencia

Showing 10 posts of 10 posts found.

bms

European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

News
shutterstock_179291957

CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment

July 25, 2016
Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis

Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …

News

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

News
Orencia image

BMS backs rheumatoid arthritis prevention trial

March 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis

Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …

News
Lonza image

BMS and Lonza announce expansion plans

October 31, 2014
Manufacturing and Production, Sales and Marketing BMS, Lonza, Orencia, manufacturing, opdivo

Bristol-Myers Squibb (BMS) and Lonza are to expand upon an existing manufacturing agreement to meet anticipated demand for commercial biologics. …

News
Orencia image

Orencia matches Humira

June 13, 2013
Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA

Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …

News
RoActemra image

RoActemra superior to Humira as single-agent therapy

June 7, 2012
Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA

Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …

News

NICE says no to BMS for second-line Orencia

August 25, 2011
Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis

In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …

News

NICE re-thinks arthritis guidance

June 25, 2010
Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …

News
Orencia

Orencia wins expanded European licence

January 27, 2010
Sales and Marketing BMS, Orencia, rheumatoid arthritis

BMS’s Orencia has been approved in Europe to treat children aged six and over who suffer from a form of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026